/
DCF Valuation
Base-case fair value
$156.29
Intrinsic $208.39 · 25% MOS
Current price: $33.37
Base-case summary
Our base-case DCF for Rigel Pharmaceuticals Inc (RIGL) projects 10 years of free cash flow growth at 20.0% for years 1–5 and 10.0% for years 6–10, anchored to 72.1% historical FCF growth, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $79M in trailing free cash flow, this produces an intrinsic value of $208.39 per share. A 25% safety margin gives a fair value of $156.29, suggesting the stock is currently 368% undervalued against the $33.37 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$79M
Cash & equivalents
$147M
Total debt
$46M
Shares outstanding
20M